Trials / Completed
CompletedNCT06871761
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 Injection With Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin, Metformin in Combination With or Without One Other Oral Antidiabetic Drug (OAD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 393 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR17031 injection | HR17031 injection |
| DRUG | insulin glargine | insulin glargine |
Timeline
- Start date
- 2024-05-08
- Primary completion
- 2025-05-13
- Completion
- 2025-05-13
- First posted
- 2025-03-12
- Last updated
- 2026-01-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06871761. Inclusion in this directory is not an endorsement.